Why the study?
Real-world evidence was needed to evaluate the achievement rate of guideline-recommended target blood pressure and safety of treatment incorporating sacubitril/valsartan in Japanese patients with essential hypertension.
Does sacubitril/valsartan improve achievement of guideline-recommended blood pressure targets in Japanese patients with essential hypertension?
Does sacubitril/valsartan improve achievement of guideline-recommended blood pressure targets in Japanese patients with essential hypertension?
In a real-world Japanese cohort, sacubitril/valsartan significantly reduced blood pressure and helped nearly 30% of patients achieve guideline-recommended targets within 8 weeks with an acceptable safety profile.
Answers are grounded in this paper and cite their sources.
Supports real-world BP lowering in Japanese hypertension; leaves open randomized confirmation of target achievement.
This real-world, non-interventional, retrospective cohort study evaluated the achievement rate of guideline-recommended target blood pressure (BP) and representative safety profile of the treatment incorporating sacubitril/valsartan (Sac/Val) in Japanese patients with essential hypertension. Data were collected from electronic health records from ~4700 clinics across Japan, covering ~11.4% of the nationwide population. Of the 1405 eligible patients, 1247 were included in the effectiveness analysis. The primary endpoint investigated the proportion of patients achieving the Japanese Society of Hypertension 2019-recommended antihypertensive goals within 8 weeks of initial Sac/Val administration (index date). Secondary endpoints included description of baseline characteristics and their relative contribution to BP goal attainment, description of prescription patterns, and safety. A total of 29.8% of patients achieved individual estimated BP goals, with significant mean reductions in systolic and diastolic BPs (-15.6 mmHg and -6.1 mmHg, respectively, p < 0.0001). Patients aged ≥75 years, those with cerebrovascular disease, and those classified as Grade I hypertension were more likely to meet BP goals. Among patients with BP reduction of ≥10 mmHg, the most common prescription pattern at index date was a combination of calcium channel blocker (CCB) and Sac/Val, and a majority switched from CCB and angiotensin receptor blocker combination or were on CCB monotherapy. The most common signs of adverse events were hypotension and diuresis-related events, particularly during summer. The discontinuation rates following these signs were 1.0% and 0.8%. This real-world study demonstrated the clinical utility and representative safety profile of treatments involving Sac/Val in Japanese patients with essential hypertension.
No takes yet. Share an insight, caveat, or question.
Katsuya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: